Raji Sara, Sahranavard Mehrdad, Mottaghi Mahdi, Sahebkar Amirhossein
Persian Cohort Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Cancer Cell Int. 2022 Apr 26;22(1):163. doi: 10.1186/s12935-022-02584-0.
Delayed cancer diagnosis and inefficient cancer prognosis determination are problems faced in cancer diagnosis and treatment. MicroRNAs (miRs), especially miR-212, have shown a promise in cancer diagnosis and prognosis. Herein, we performed a systematic review and meta-analysis to assess the prognostic and diagnostic value of miR-212 level in cancer and evaluated its association with patient characteristics.
A fully electronic literature search using related keywords was performed in PubMed, Scopus, Web of Science, Embase, and ScienceDirect databases by June 6, 2021, with no time or language restriction. Meta-analysis was performed to pool survival prognosis data using hazard ratio (HR), association using odds ratio (OR), and diagnostic data using sensitivity, specificity, and diagnostic odds ratio (DOR). Sub-group analysis and meta-regression were performed as appropriate.
Results of 28 studies on 1880 patients showed a poor cancer prognosis with high levels of miR-212 in pancreatic ductal adenocarcinoma (PDAC, HR = 2.451 [1.447-4.149]), and a poor cancer prognosis with low levels of miR-212 in other cancers (HR = 2.514 [2.162-2.923]). Higher alpha-fetoprotein (AFP) level and Edmondson-Steiner grade were factors associated with miR-212 low level incidence. Diagnostic odds ratio 10.688 (3.644-31.348) and SROC AUC of 0.84 confirmed high diagnostic performance of miR-212.
Our systematic review and meta-analysis results confirm miR-212 high value in cancer prognosis and diagnosis. High level of miR-212 showed poor prognosis in PDAC and low level of miR-212 showed poor prognosis in other cancers. in conclusion, miR-212 could be a novel potential biomarker in cancer diagnosis and prognosis.
癌症诊断和治疗中面临癌症诊断延迟和癌症预后判定效率低下的问题。微小RNA（miR），尤其是miR-212，在癌症诊断和预后方面已展现出前景。在此，我们进行了一项系统评价和荟萃分析，以评估miR-212水平在癌症中的预后和诊断价值，并评估其与患者特征的关联。
截至2021年6月6日，在PubMed、Scopus、Web of Science、Embase和ScienceDirect数据库中使用相关关键词进行了全面的电子文献检索，无时间或语言限制。使用风险比（HR）汇总生存预后数据、使用比值比（OR）汇总关联数据以及使用敏感度、特异度和诊断比值比（DOR）汇总诊断数据进行荟萃分析。酌情进行亚组分析和荟萃回归。
对1880例患者的28项研究结果显示，在胰腺导管腺癌（PDAC）中，miR-212水平高提示癌症预后不良（HR = 2.451 [1.447 - 4.149]），在其他癌症中，miR-212水平低提示癌症预后不良（HR = 2.514 [2.162 - 2.923]）。较高的甲胎蛋白（AFP）水平和Edmondson-Steiner分级是与miR-212低水平发生率相关的因素。诊断比值比为10.688（3.644 - 31.348）且SROC曲线下面积为0.84证实了miR-212具有较高的诊断效能。
我们的系统评价和荟萃分析结果证实了miR-212在癌症预后和诊断方面具有较高价值。miR-212水平高在PDAC中提示预后不良，miR-212水平低在其他癌症中提示预后不良。总之，miR-212可能是癌症诊断和预后中的一种新型潜在生物标志物。
Zotero 插件